Malignancy risk in Korean male patients with ankylosing spondylitis
- 65 Downloads
The objective of this study is to determine the overall and specific cancer risks in male patients with ankylosing spondylitis (AS). From the claims database of the Health Insurance and Review Assessment, male patients with AS without prior cancer history were selected (n = 21,780). Stratified random samples of claims data were used as a reference general male population group (n = 342,361). Incidence rates of overall and types of cancer were presented as number of events per 10,000 person-years with 95% confidence interval (CI). A standardized incidence ratio (SIR) was used to represent the association between AS and cancer, accounting for person-years at risk. Compared to a general male population group, the overall incidence of cancer was increased in male patients with AS (SIR 1.25, 95% CI 1.15–1.36). For specific malignancy types, the risks of male reproductive system malignancy (SIR 1.97, 95% CI 1.59–2.35) and pancreatic cancer (SIR 1.75, 95% CI 1.12–2.37) were increased. Male patients with AS had increased cancer risk, especially for male reproductive system and pancreatic cancer.
KeywordsAnkylosing spondylitis Cancer Risk Standardized incidence ratio
Conceptualization: HK, SKC, YKS, THK. Formal analysis: HK, EJJ. Investigation: BN, HK. Methodology: YKS, EJJ. Writing—original draft: BN. Writing—review and editing: YKS, THK.
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
To protect patient privacy, the National Health Insurance (NHI) stores beneficiary identifications in an encrypted format and provides data to the public without individual identifiers. Using these data allowed our study to be included in exemption categories (Institutional Review Board file no. HYUH 2018-12-027).
Conflict of interest
The authors have declared no conflicts of interest.
- 11.Hellgren K, Smedby KE, Backlin C, Sundstrom C, Feltelius N, Eriksson JK, Baecklund E, Askling J (2014) Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol 66(5):1282–1290. https://doi.org/10.1002/art.38339 CrossRefGoogle Scholar
- 13.Kim JA, Yoon S, Kim LY, Kim DS (2017) Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 32(5):718–728. https://doi.org/10.3346/jkms.2017.32.5.718 CrossRefGoogle Scholar
- 18.Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, Ollier WE, Martin J, Gonzalez-Gay MA (2007) Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum 37(1):31–38. https://doi.org/10.1016/j.semarthrit.2007.01.002 CrossRefGoogle Scholar
- 23.Hammer RE, Richardson JA, Simmons WA, White AL, Breban M, Taurog JD (1995) High prevalence of colorectal cancer in HLA-B27 transgenic F344 rats with chronic inflammatory bowel disease. J Investig Med 43(3):262–268Google Scholar
- 26.Bostwick DG, Liu L, Brawer MK, Qian J (2004) High-grade prostatic intraepithelial neoplasia. Rev Urol 6(4):171–179Google Scholar
- 27.Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, Group RS (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362(13):1192–1202. https://doi.org/10.1056/nejmoa0908127 CrossRefGoogle Scholar
- 28.Straub RH, Struharova S, Scholmerich J, Harle P (2002) No alterations of serum levels of adrenal and gonadal hormones in patients with ankylosing spondylitis. Clin Exp Rheumatol 20(6 Suppl 28):S52–S59Google Scholar
- 32.Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B (2013) Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 19(4):789–799. https://doi.org/10.1097/MIB.0b013e31828029c0 CrossRefGoogle Scholar
- 33.Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D, Force USPST (2007) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 146(5):376–389CrossRefGoogle Scholar
- 35.Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET, Investigators APCS (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873–884. https://doi.org/10.1056/NEJMoa061355 CrossRefGoogle Scholar
- 37.Burr NE, Talboys RJ, Savva S, Clark A, Phillips M, Metcalfe M, Dennison A, Robinson R, Lewis MP, Rhodes M, Rushbrook S, Hart AR (2014) Aspirin may prevent cholangiocarcinoma: a case-control study from the United kingdom. Dig Dis Sci 59(7):1567–1572. https://doi.org/10.1007/s10620-014-3056-z CrossRefGoogle Scholar